Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPN-101 in Aicardi-Goutières syndrome
ISRCTN15569205Phase 2Terminated
- Sponsor
- Transposon Therapeutics, Inc.
- Start
- Oct 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of censavudine in Aicardi-Goutières syndrome (AGS), sponsored by Transposon Therapeutics, Inc. Primary endpoints: Reduction in innate immune signaling and Treatment-emergent adverse events. Started Oct 2023; status: terminated.
02
Drugs
censavudine
03
Conditions
Aicardi-Goutières syndrome (AGS)
Beyond the preview
Go deeper on ISRCTN15569205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15569205.